1-3 of 3
Meera Patturajan
Close
Sort by
Journal Articles

A Phase 2a Study Evaluating the Safety and Pharmacokinetics (PK) of Luspatercept in Pediatric Patients with Transfusion-Dependent β-Thalassemia (TDT)

Vip Viprakasit, Thomas D. Coates, Khaled M. Musallam, Julie Vienne Buerki, Meera Patturajan, Natalia Holot, Yesim Aydinok
Journal: Blood
Blood (2021) 138 (Supplement 1): 4161.
https://doi.org/10.1182/blood-2021-145698
Published: 2021
Journal Articles

Efficacy, Safety, and Pharmacokinetics (PK) of Azacitidine (AZA) in Children and Young Adults with Acute Myeloid Leukemia (AML) in the Phase 2 AZA-AML-004 Trial

Dirk Reinhardt, MD, Henrik Hasle, PhD, Karsten Nysom, André Baruchel, Franco Locatelli, MD PhD, Bouchra Benettaib, Noha Biserna, Meera Patturajan, Mathew Simcock, Allison Gaudy, C. Michel Zwaan
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–11.
https://doi.org/10.1182/blood-2020-137043
Published: 2020
Journal Articles

Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study

Marek Trneny, Thierry Lamy, Jan Walewski, Wojciech Jurczak, David Belada, MD, Jiri Mayer, Prof., MD PhD, John Radford, Julia Alexeeva, Dzhelil Osmanov, Tsvetan Biyukov, Meera Patturajan, Marie-Laure Casadebaig Bravo, Luca Arcaini
Journal: Blood
Blood (2014) 124 (21): 626.
https://doi.org/10.1182/blood.V124.21.626.626
Published: 2014